Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy

Uday C Ghoshal, Ratnakar Shukla, Ujjala Ghoshal, Uday C Ghoshal, Ratnakar Shukla, Ujjala Ghoshal

Abstract

The pathogenesis of irritable bowel syndrome (IBS), once thought to be largely psychogenic in origin, is now understood to be multifactorial. One of the reasons for this paradigm shift is the realization that gut dysbiosis, including small intestinal bacterial overgrowth (SIBO), causes IBS symptoms. Between 4% and 78% of patients with IBS and 1% and 40% of controls have SIBO; such wide variations in prevalence might result from population differences, IBS diagnostic criteria, and, most importantly, methods to diagnose SIBO. Although quantitative jejunal aspirate culture is considered the gold standard for the diagnosis of SIBO, noninvasive hydrogen breath tests have been popular. Although the glucose hydrogen breath test is highly specific, its sensitivity is low; in contrast, the early-peak criteria in the lactulose hydrogen breath test are highly nonspecific. Female gender, older age, diarrhea-predominant IBS, bloating and flatulence, proton pump inhibitor and narcotic intake, and low hemoglobin are associated with SIBO among IBS patients. Several therapeutic trials targeting gut microbes using antibiotics and probiotics have further demonstrated that not all symptoms in patients with IBS originate in the brain but rather in the gut, providing support for the micro-organic basis of IBS. A recent proof-of-concept study showing the high frequency of symptom improvement in patients with IBS with SIBO further supports this hypothesis.

Keywords: Bacterial overgrowth; Breath tests; Dysbiosis; Gastrointestinal microbiota; Probiotics; Rifaximin.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Schematic diagram showing the frequency of small intestinal bacterial overgrowth (SIBO) using quantitative jejunal aspirate culture, glucose and lactulose hydrogen breath tests (GHBT and LHBT, respectively) among patients with irritable bowel syndrome (IBS), gut defense mechanisms that prevent the development of SIBO, factors associated with SIBO among patients with IBS, and mechanisms of IBS symptom development. As shown in the figure, the frequency of SIBO in IBS patients using LHBT (early-peak criteria) is higher than that by using upper gut aspirate culture and GHBT (LHBT [45%]; upper gut aspirate culture [23%] and GHBT [26%]). Moreover, SIBO is more frequent in healthy controls using LHBT due to false positive test results (LHBT [21%], upper gut aspirate culture [1%] and GHBT [5%]). GI, gastrointestinal; IBS-D, irritable bowel syndrome, diarrhea-predominan; PPI, proton pump inhibitor; CHO, carbohydrate.

References

    1. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014;20:8796–8806.
    1. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085. doi: 10.1155/2012/151085.
    1. Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532–4540. doi: 10.3748/wjg.v16.i36.4532.
    1. Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23. doi: 10.1186/1471-230X-10-23.
    1. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852–858. doi: 10.1001/jama.292.7.852.
    1. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 2007;3:112–122.
    1. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20:2482–2491. doi: 10.3748/wjg.v20.i10.2482.
    1. Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil. 2008;20:998–1008. doi: 10.1111/j.1365-2982.2008.01142.x.
    1. Levenstein S, Rosenstock S, Jacobsen RK, Jorgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015;13:498–506.e1. doi: 10.1016/j.cgh.2014.07.052.
    1. Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4:5–19. doi: 10.12998/wjcc.v4.i1.5.
    1. Wang L, Tan RZ, Chen Y, et al. CagA promotes proliferation and secretion of extracellular matrix by inhibiting signaling pathway of apoptosis in rat glomerular mesangial cells. Ren Fail. 2016;38:458–464. doi: 10.3109/0886022X.2016.1138831.
    1. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011;6:209–240. doi: 10.1007/s12263-011-0229-7.
    1. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904. doi: 10.1152/physrev.00045.2009.
    1. Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol. 2010;25:244–251. doi: 10.1111/j.1440-1746.2009.06133.x.
    1. Lagier JC, Million M, Hugon P, Armougom F, Raoult D. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol. 2012;2:136. doi: 10.3389/fcimb.2012.00136.
    1. Nigam D. Microbial interactions with humans and animals. Int J Microbiol Allied Sci. 2015;2:1–17.
    1. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638. doi: 10.1126/science.1110591.
    1. Schloss PD, Handelsman J. Status of the microbial census. Microbiol Mol Biol Rev. 2004;68:686–691. doi: 10.1128/MMBR.68.4.686-691.2004.
    1. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–693. doi: 10.1038/sj.embor.7400731.
    1. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012:872716. doi: 10.1155/2012/872716.
    1. Goulet O, Joly F. Intestinal microbiota in short bowel syndrome. Gastroenterol Clin Biol. 2010;34(Suppl 1):S37–S43. doi: 10.1016/S0399-8320(10)70019-1.
    1. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–2990. doi: 10.3748/wjg.v16.i24.2978.
    1. Vanderhoof JA, Young RJ. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth: treatment of bacterial overgrowth. UpToDate Online. 2010;18
    1. Gabrielli M, D’Angelo G, Di Rienzo T, Scarpellini E, Ojetti V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):30–35.
    1. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol. 2004;268:491–502.
    1. Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Thomas MC, Bolin TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494–500. doi: 10.1111/j.1572-0241.2001.03533.x.
    1. Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–489. doi: 10.1111/nmo.12516.
    1. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011;5:253–266. doi: 10.5009/gnl.2011.5.3.253.
    1. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol. 2009;15:2628–2631. doi: 10.3748/wjg.15.2628.
    1. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep. 2007;9:463–467. doi: 10.1007/s11894-007-0060-x.
    1. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with orocecal transit time. Indian J Gastroenterol. 2006;25:6–10.
    1. Britton E, McLaughlin JT. Ageing and the gut. Proc Nutr Soc. 2013;72:173–177. doi: 10.1017/S0029665112002807.
    1. Ghoshal U, Ghoshal UC, Ranjan P, Naik SR, Ayyagari A. Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. BMC Gastroenterol. 2003;3:9. doi: 10.1186/1471-230X-3-9.
    1. Lagier JC, Armougom F, Million M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect. 2012;18:1185–1193. doi: 10.1111/1469-0691.12023.
    1. Kokcha S, Mishra AK, Lagier JC, et al. Non contiguous-finished genome sequence and description of Bacillus timonensis sp. nov. Stand Genomic Sci. 2012;6:346–355. doi: 10.4056/sigs.2776064.
    1. Ghoshal UC. How to interpret hydrogen breath tests. J Neurogastroenterol Motil. 2011;17:312–317. doi: 10.5056/jnm.2011.17.3.312.
    1. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391–1395. doi: 10.1111/j.1365-2036.2005.02493.x.
    1. Abraczinskas D, Goldfinger SE. Intestinal gas and bloating. Up-ToDate Online. 2010:18.
    1. Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol. 2014;26:753–760. doi: 10.1097/MEG.0000000000000122.
    1. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506. doi: 10.1111/j.1572-0241.2000.03368.x.
    1. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982–988. doi: 10.1016/0016-5085(88)90173-4.
    1. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2441–2449. doi: 10.1007/s10620-010-1276-4.
    1. Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55:297–303. doi: 10.1136/gut.2005.075127.
    1. Ojetti V, Di Rienzo TA, D’Angelo G, et al. Early peak of hydrogen during lactose breath test predicts intestinal motility. Open J Gastroenterol. 2014;4:40–44. doi: 10.4236/ojgas.2014.41007.
    1. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334–340. doi: 10.1136/gut.2009.205476.
    1. Santavirta J. Lactulose hydrogen and [14C]xylose breath tests in patients with ileoanal anastomosis. Int J Colorectal Dis. 1991;6:208–211. doi: 10.1007/BF00341392.
    1. Banik GD, Maity A, Som S, et al. Diagnosis of small intestinal bacterial overgrowth in irritable bowel syndrome patients using high-precision stable 13 CO 2/12 CO 2 isotope ratios in exhaled breath. J Anal At Spectrom. 2014;29:1918–1924. doi: 10.1039/C4JA00186A.
    1. Ghoshal UC, Ghoshal U, Ayyagari A, et al. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time. J Gastroenterol Hepatol. 2003;18:540–547. doi: 10.1046/j.1440-1746.2003.03006.x.
    1. Lu CL, Chen CY, Chang FY, Lee SD. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study. Clin Sci (Lond) 1998;95:165–169. doi: 10.1042/cs0950165.
    1. Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitraşcu DL. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin: a pilot study. Rom J Intern Med. 2013;51:143–147.
    1. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16:40–46. doi: 10.5056/jnm.2010.16.1.40.
    1. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808. doi: 10.1136/gut.2006.108712.
    1. Kerckhoffs AP, Visser MR, Samsom M, et al. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol. 2008;42:1095–1102. doi: 10.1097/MCG.0b013e31818474d7.
    1. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329. doi: 10.1007/s10620-012-2033-7.
    1. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570. doi: 10.1111/j.1572-0241.2005.40795.x.
    1. Zhao J, Zheng X, Chu H, et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic orocecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil. 2014;26:794–802. doi: 10.1111/nmo.12331.
    1. Park JS, Yu JH, Lim HC, et al. Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome. Korean J Gastroenterol. 2010;56:242–248. doi: 10.4166/kjg.2010.56.4.242.
    1. Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416–420. doi: 10.1016/j.jpeds.2009.03.033.
    1. Carrara M, Desideri S, Azzurro M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2008;12:197–202.
    1. Mann NS, Limoges-Gonzales M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome. Hepatogastroenterology. 2009;56:718–721.
    1. Rana SV, Sinha SK, Sikander A, Bhasin DK, Singh K. Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study. Trop Gastroenterol. 2008;29:23–25.
    1. Yakoob J, Abbas Z, Khan R, Hamid S, Awan S, Jafri W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011;17:371–375. doi: 10.4103/1319-3767.87176.
    1. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.
    1. Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26(Suppl 3):135–138. doi: 10.1111/j.1440-1746.2011.06654.x.
    1. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89–95.
    1. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160. doi: 10.1111/j.1365-2036.2005.02690.x.
    1. Rana SV, Sharma S, Kaur J, Sinha SK, Singh K. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85:243–247. doi: 10.1159/000336174.
    1. Abbasi MH, Zahedi M, Darvish Moghadam S, Shafieipour S, HayatBakhsh Abbasi M. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East J Dig Dis. 2015;7:36–40.
    1. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279–1286. doi: 10.1016/j.cgh.2009.06.031.
    1. Moraru IG, Moraru AG, Andrei M, et al. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome: evidence from a multicentre study in Romania. Rom J Intern Med. 2014;52:143–150.
    1. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol. 2004;7:19–28. doi: 10.1007/s11938-004-0022-4.
    1. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57–62. doi: 10.1136/gutjnl-2015-309618.
    1. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972–2976. doi: 10.1111/j.1572-0241.2008.01992.x.
    1. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059–1067. doi: 10.1111/j.1365-2036.2011.04625.x.
    1. Gasbarrini A, Scarpellini E, Gabrielli M, Tortora A, Purchiaroni F, Ojetti V. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1378–1379. doi: 10.1111/j.1365-2036.2011.04657.x.
    1. Haderstorfer B, Psycholgin D, Whitehead WE, Schuster MM. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol. 1989;84:375–378.
    1. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013;4:223–231. doi: 10.1177/2040622313496126.
    1. Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig Dis Sci. 2015;60:2953–2962. doi: 10.1007/s10620-015-3607-y.
    1. Park H. The role of small intestinal bacterial overgrowth in the pathophysiology of irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:3–4. doi: 10.5056/jnm.2010.16.1.3.
    1. Choi CH, Chang SK. Role of small intestinal bacterial overgrowth in functional gastrointestinal disorders. J Neurogastroenterol Motil. 2016;22:3–5. doi: 10.5056/jnm15196.
    1. Barbara G, Feinle-Bisset C, Ghoshal UC, et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305–1318.e8. doi: 10.1053/j.gastro.2016.02.028.
    1. Francisconi CF, Sperber AD, Fang X, et al. Multicultural aspects in functional gastrointestinal disorders (FGIDs) Gastroenterology. 2016;150:1344–1354. doi: 10.1053/j.gastro.2016.02.013.
    1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407. doi: 10.1053/j.gastro.2016.02.031.
    1. Pimentel M, Gunsalus RP, Rao SS, Zhang H. Methanogens in human health and disease. Am J Gastroenterol Suppl. 2012;1:28–33. doi: 10.1038/ajgsup.2012.6.
    1. Fan X, Sellin JH. Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther. 2009;29:1069–1077. doi: 10.1111/j.1365-2036.2009.03970.x.
    1. Riepe SP, Goldstein J, Alpers DH. Effect of secreted Bacteroides proteases on human intestinal brush border hydrolases. J Clin Invest. 1980;66:314–322. doi: 10.1172/JCI109859.
    1. Zaidel O, Lin HC. Uninvited guests: the impact of small intestinal bacterial overgrowth on nutritional status. Pract Gastroenterol. 2003;27:27–34.
    1. Bala L, Ghoshal UC, Ghoshal U, et al. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn Reson Med. 2006;56:738–744. doi: 10.1002/mrm.21041.
    1. Ghoshal UC, Kumar S, Misra A, Choudhuri G. Pathogenesis of tropical sprue: a pilot study of antroduodenal manometry, duodenocaecal transit time & fat-induced ileal brake. Indian J Med Res. 2013;137:63–72.
    1. Donowitz JR, Petri WA., Jr Pediatric small intestine bacterial overgrowth in low-income countries. Trends Mol Med. 2015;21:6–15. doi: 10.1016/j.molmed.2014.11.001.
    1. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306–314. doi: 10.1038/nrgastro.2009.35.
    1. Malbert CH. The ileocolonic sphincter. Neurogastroenterol Motil. 2005;17(Suppl 1):41–49. doi: 10.1111/j.1365-2982.2005.00657.x.
    1. Dass NB, John AK, Bassil AK, et al. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Neurogastroenterol Motil. 2007;19:66–74. doi: 10.1111/j.1365-2982.2006.00853.x.
    1. Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100:2560–2568. doi: 10.1111/j.1572-0241.2005.00230.x.
    1. Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol. 2006;4:11–20. doi: 10.1016/j.cgh.2005.10.020.
    1. Srivastava D, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408–1416. doi: 10.1111/nmo.12399.
    1. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol. 2012;33:251–256. doi: 10.7869/tg.2012.66.
    1. Spinucci G, Guidetti M, Lanzoni E, Pironi L. Endogenous ethanol production in a patient with chronic intestinal pseudo-obstruction and small intestinal bacterial overgrowth. Eur J Gastroenterol Hepatol. 2006;18:799–802. doi: 10.1097/01.meg.0000223906.55245.61.
    1. Schmulson M, Bielsa MV, Carmona-Sánchez R, et al. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex. 2014;79:96–134.
    1. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421–431. doi: 10.1007/s00535-011-0379-9.
    1. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:21–43. doi: 10.1016/j.gtc.2010.12.004.
    1. Patacchini R, Santicioli P, Giuliani S, Maggi CA. Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol. 2005;509:171–177. doi: 10.1016/j.ejphar.2005.01.005.
    1. Weinstock LB, Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci. 2008;53:1246–1251. doi: 10.1007/s10620-007-0022-z.
    1. Banik GD, De A, Som S, et al. Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS. J Breath Res. 2016;10:026010. doi: 10.1088/1752-7155/10/2/026010.
    1. Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452. doi: 10.1136/ard.2003.011502.
    1. Kwon JG, Park KS, Park JH, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol. 2011;57:82–99. doi: 10.4166/kjg.2011.57.2.82.
    1. Neale G, Gompertz D, Schönsby H, Tabaqchali S, Booth CC. The metabolic and nutritional consequences of bacterial overgrowth in the small intestine. Am J Clin Nutr. 1972;25:1409–1417.
    1. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781–786. doi: 10.1111/j.1365-2036.2007.03259.x.
    1. Di Stefano M, Miceli E, Missanelli A, Corazza GR. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci. 2005;9:217–222.
    1. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(2 Suppl1):S78–S90. doi: 10.1053/j.gastro.2005.11.046.
    1. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3:16–24. doi: 10.7453/gahmj.2014.019.
    1. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31–35. doi: 10.1111/j.1365-2036.2005.02516.x.
    1. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.
    1. Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28:281–289. doi: 10.1097/MEG.0000000000000557.
    1. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. doi: 10.1056/NEJMoa1004409.
    1. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–S26. doi: 10.1038/ajg.2014.187.
    1. Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2015;11(4 Suppl 2):1–19.
    1. Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1146–1148. doi: 10.1053/j.gastro.2014.09.001.
    1. Attar A, Flourié B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794–797. doi: 10.1016/S0016-5085(99)70336-7.
    1. Gatta L, Scarpignato C. Mo2055 Rifaximin for treatment of small intestine bacterial overgrowth (SIBO): a systematic review and meta-analysis. Gastroenterology. 2013;144(5 Suppl 1):S729. doi: 10.1016/S0016-5085(13)62707-9.
    1. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–934. doi: 10.1111/apt.12479.
    1. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17:252–266. doi: 10.5056/jnm.2011.17.3.252.
    1. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2:221–238. doi: 10.1177/1756283X09104794.
    1. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. doi: 10.1053/j.gastro.2004.11.050.
    1. Thijssen AY, Jonkers D, Clemens CH, Masclee A. Effect of probiotic treatment on visceral hypersensitivity in irritable bowel syndrome. Gastroenterology. 2011;140(5 Suppl 1):S852.
    1. Lyszkowska M, Popinska K, Idzik M, Ksiazyk P. Probiotics in children with gut failure. J Pediatr Gastroenterol Nutr. 2008;46:543.
    1. Rosania R, Giorgio F, Principi M, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013;8:169–172. doi: 10.2174/15748847113089990048.
    1. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904. doi: 10.1046/j.1365-2036.2003.01543.x.
    1. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–696. doi: 10.1111/j.1365-2982.2005.00695.x.
    1. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–2643. doi: 10.1023/A:1021039032413.
    1. Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y) 2009;5:435–442.
    1. Shepherd SJ, Halmos E, Glance S. The role of FODMAPs in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2014;17:605–609. doi: 10.1097/MCO.0000000000000116.
    1. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.e5. doi: 10.1053/j.gastro.2013.09.046.
    1. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccha-rides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. 2012;5:261–268. doi: 10.1177/1756283X11436241.
    1. Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y) 2014;10:164–174.
    1. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366–1373. doi: 10.1111/j.1440-1746.2010.06370.x.
    1. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metage-nomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14. doi: 10.1126/scitranslmed.3000322.
    1. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012;4:1095–1119. doi: 10.3390/nu4081095.
    1. Zimmer J, Lange B, Frick JS, et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr. 2012;66:53–60. doi: 10.1038/ejcn.2011.141.
    1. Ghoshal UC, Singh R. Frequency and risk factors of functional gastro-intestinal disorders in a rural Indian population. J Gastroenterol Hepatol. Epub 2016 Jun 5. .
    1. Drossman DA. Guidelines for use of the multi-dimensional clinical profile. In: Drossman DA, Azpiroz F, Chang L, et al., editors. Multi-dimensional clinical profile (MDCP): for functional gastrointestinal disorders. Raleigh: Rome Foundation; 2015. pp. 7–14.
    1. Lindberg DA. Hydrogen breath testing in adults: what is it and why is it performed? Gastroenterol Nurs. 2009;32:19–24. doi: 10.1097/SGA.0b013e3181965d2d.
    1. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504–508. doi: 10.1016/j.cgh.2009.12.022.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe